COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

Thromb Res. 2020 Dec:196:483-485. doi: 10.1016/j.thromres.2020.10.004. Epub 2020 Oct 15.

Abstract

  1. -

    COVID-19 patients are at increased risk of thromboembolic complications.

  2. -

    Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events.

  3. -

    The bleeding risk is highest for patients treated with therapeutic anticoagulation.

Keywords: Anticoagulation; COVID; Escalated-dose; Hemorrhage; Thromboembolism; Thromboprophylaxis; VTE.

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • COVID-19 / complications
  • COVID-19 / diagnosis
  • COVID-19 / mortality
  • COVID-19 Drug Treatment*
  • Female
  • Hemorrhage / chemically induced
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Thrombosis / diagnosis
  • Thrombosis / etiology
  • Thrombosis / mortality
  • Thrombosis / prevention & control*
  • Time Factors
  • Treatment Outcome
  • Venous Thromboembolism / diagnosis
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / mortality
  • Venous Thromboembolism / prevention & control*

Substances

  • Anticoagulants